SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1706<b>Takeda, Amgen to suspend trials of cancer drug</b> reuters.com idos-11/20/2008
1705CS: Amgen Inc. (AMGN) Outperform M. Aberman CP: US$ 58.87 TP: US$ 72 CAP: US$ 62mopgcw-11/10/2008
1704Amgen Anemia-Drug Woes Will Bottom Out, Chief Says By RON WINSLOW NOVEMBER 7, Doc Bones-11/7/2008
1703CS: Amgen Inc. (AMGN) Outperform M. Aberman CP: US$ 49.70 TP: US$ 72 CAP: US$ 52mopgcw-10/24/2008
1702Amgen profits surge on reduced expenses [up over 2 in AH] Wednesday, October 22JGoren-10/22/2008
1701Roche Barred by Judge From Selling Mircera in U.S. (Update2) By William McQuilDoc Bones-10/3/2008
1700The data presented at the American Society of Bone and Mineral Research showed tdavid nordic-9/30/2008
1699I wonder how much Amgen's success with Denosumab had in this decision. In asteve kammerer-9/26/2008
1698CS: Amgen Inc. (AMGN) Outperform M. Aberman CP: US$ 59.93 TP: US$ 72 CAP: US$ 63mopgcw-9/26/2008
1697Citi: 16 September 2008 - 7 pages Amgen Inc (AMGN) mopgcw-9/22/2008
1696By Brian Orelli September 17, 2008 Sometimes the devil really is in the detaidavid nordic19/19/2008
1695J&J Touts Psoriasis-Drug Data By PETER LOFTUS SEPTEMBER 19, 2008 JohnsonDoc Bones-9/19/2008
1694Amgen's Bone-Strengthening Drug Clears Big Hurdle By RON WINSLOW SEPTEMBERDoc Bones-9/17/2008
1693<i> Effectiveness means nothing </i> uhh..ok...sure. <i> Notmopgcw-9/10/2008
16921st-line Potential - Encouragingly, the physician expects to use denosumab in ndavid nordic-9/10/2008
1691Citi: 2 September 2008 - 11 pages Amgen Inc (AMGN) mopgcw-9/10/2008
1690CS take: Denosumab uncertainty to be answered at ASBMR: Amgen will be presentinmopgcw-9/10/2008
1689Amgen Isn't Seeking A Partner for Bone Drug September 10, 2008; Page B9 ADoc Bones-9/10/2008
1688Amgen Blood-Disorder Drug Gains Clearance By DAVID J. REYNOLDS August 23, 2008;Doc Bones-8/25/2008
1687Amgen's $30 Billion Riddle - Biotech Or Big Pharma? (AMGN) August 07, 2008 |JGoren-8/8/2008
1686Looks like Merrill had it about right Specific tumor types not eliminated Basedtom pope-7/31/2008
1685Amgen Told to Reword Drug Label [NYT] By ANDREW POLLACK Published: July 31, 200Doc Bones-7/31/2008
1684Merrill - upgrade to buy. Granularity seems to be becoming a favorite jargon wortom pope-7/29/2008
1683Amgen's Profit Declines 7.7% Sales of Anemia Drugs Spur Rise in Forecast; Doc Bones-7/29/2008
1682Merrill Dmab reduces fracture incidence at 3 sites After market close on Fridaytom pope-7/28/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News